Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

doi:10.1084/jem.161.5.1122

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Greenberg, P. D.
	Articles by Cheever, M. A.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Greenberg, P. D.
	Articles by Cheever, M. A.


Social Bookmarking

	What's this?

ARTICLES

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

PD Greenberg, DE Kern and MA Cheever

The ability of noncytolytic Lyt-1+,2- T cells immune to FBL-3 leukemia to effect eradication of disseminated FBL-3 was studied. Adult thymectomized, irradiated, and T-depleted bone marrow-reconstituted (ATXBM) B6 hosts were cured of disseminated FBL-3 by treatment with 180 mg/kg cyclophosphamide (CY) and adoptively transferred Lyt-1+,2- T cells obtained from congenic B6/Thy-1.1 donors immune to FBL-3. Analysis of the T cell compartment of ATXBM hosts treated and rendered tumor-free by this therapy revealed that the only T cells present in the mice were donor-derived Lyt-1+,2- T cells. In vitro stimulation of these T cells with FBL-3 tumor cells, which express class I but no class II major histocompatibility complex antigens, induced lymphokine secretion, but did not result in the generation of cytotoxic T lymphocytes (CTL). Thus, in a setting in which mice lack Lyt-2+ T cells, and in which no CTL of either host or donor origin could be detected, immune Lyt-1+,2- T cells, in conjunction with CY, mediated eradication of a disseminated leukemia. The results suggest that delayed-type hypersensitivity responses induced by immune T cells represent a potentially useful effector mechanism for in vivo elimination of disseminated tumor cells.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., Gattinoni, L., Wrzesinski, C., Hinrichs, C. S., Kerstann, K. W., Feigenbaum, L., Chan, C.-C., Restifo, N. P. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373 [Abstract] [Full Text]
Willimsky, G., Czeh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P., Stein, H., Blankenstein, T. (2008). Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. JEM 205: 1687-1700 [Abstract] [Full Text]
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., Yee, C. (2008). Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. NEJM 358: 2698-2703 [Abstract] [Full Text]
Paulos, C. M., Kaiser, A., Wrzesinski, C., Hinrichs, C. S., Cassard, L., Boni, A., Muranski, P., Sanchez-Perez, L., Palmer, D. C., Yu, Z., Antony, P. A., Gattinoni, L., Rosenberg, S. A., Restifo, N. P. (2007). Toll-like Receptors in Tumor Immunotherapy. Clin. Cancer Res. 13: 5280-5289 [Abstract] [Full Text]
Zimmermann, V. S., Casati, A., Schiering, C., Caserta, S., Hess Michelini, R., Basso, V., Mondino, A. (2007). Tumors Hamper the Immunogenic Competence of CD4+ T Cell-Directed Dendritic Cell Vaccination. J. Immunol. 179: 2899-2909 [Abstract] [Full Text]
Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O., Matzinger, P. (2007). CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354 [Abstract] [Full Text]
Maksimow, M., Miiluniemi, M., Marttila-Ichihara, F., Jalkanen, S., Hanninen, A. (2006). Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity. Blood 108: 1298-1305 [Abstract] [Full Text]
Muraro, S., Bondanza, A., Bellone, M., Greenberg, P. D., Bonini, C. (2005). Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. Blood 105: 3596-3604 [Abstract] [Full Text]
Dannull, J., Nair, S., Su, Z., Boczkowski, D., DeBeck, C., Yang, B., Gilboa, E., Vieweg, J. (2005). Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 105: 3206-3213 [Abstract] [Full Text]
Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I., Marson, A. L. (2004). Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression. JEM 200: 1581-1592 [Abstract] [Full Text]
Saff, R. R., Spanjaard, E. S., Hohlbaum, A. M., Marshak-Rothstein, A. (2004). Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells. J. Immunol. 172: 6598-6606 [Abstract] [Full Text]
Schultz, E. S., Schuler-Thurner, B., Stroobant, V., Jenne, L., Berger, T. G., Thielemanns, K., van der Bruggen, P., Schuler, G. (2004). Functional Analysis of Tumor-Specific Th Cell Responses Detected in Melanoma Patients after Dendritic Cell-Based Immunotherapy. J. Immunol. 172: 1304-1310 [Abstract] [Full Text]
Zhao, Y., Boczkowski, D., Nair, S. K., Gilboa, E. (2003). Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. Blood 102: 4137-4142 [Abstract] [Full Text]
Flynn, S., Stockinger, B. (2003). Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation. Blood 101: 4472-4478 [Abstract] [Full Text]
Hess, S. D., Egilmez, N. K., Bailey, N., Anderson, T. M., Mathiowitz, E., Bernstein, S. H., Bankert, R. B. (2003). Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma}. J. Immunol. 170: 400-412 [Abstract] [Full Text]
Segal, J. G., Lee, N. C., Tsung, Y. L., Norton, J. A., Tsung, K. (2002). The Role of IFN-{gamma} in Rejection of Established Tumors by IL-12 : Source of Production and Target. Cancer Res. 62: 4696-4703 [Abstract] [Full Text]
Ohlen, C., Kalos, M., Cheng, L. E., Shur, A. C., Hong, D. J., Carson, B. D., Kokot, N. C.T., Lerner, C. G., Sather, B. D., Huseby, E. S., Greenberg, P. D. (2002). CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function. JEM 195: 1407-1418 [Abstract] [Full Text]
Roberts, W. K., Livingston, P. O., Agus, D. B., Pinilla-Ibarz, J., Zelenetz, A., Scheinberg, D. A. (2002). Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 99: 3748-3755 [Abstract] [Full Text]
Egilmez, N. K., Hess, S. D., Chen, F.-A., Takita, H., Conway, T. F., Bankert, R. B. (2002). Human CD4+ Effector T Cells Mediate Indirect Interleukin-12- and Interferon-{gamma}-dependent Suppression of Autologous HLA-negative Lung Tumor Xenografts in Severe Combined Immunodeficient Mice. Cancer Res. 62: 2611-2617 [Abstract] [Full Text]
Beck-Engeser, G. B., Monach, P. A., Mumberg, D., Yang, F., Wanderling, S., Schreiber, K., Espinosa, R. III, Le Beau, M. M., Meredith, S. C., Schreiber, H. (2001). Point Mutation in Essential Genes with Loss or Mutation of the Second Allele: Relevance to the Retention of Tumor-specific Antigens. JEM 194: 285-300 [Abstract] [Full Text]
Meyer zum Buschenfelde, C., Metzger, J., Hermann, C., Nicklisch, N., Peschel, C., Bernhard, H. (2001). The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells. J. Immunol. 167: 1712-1719 [Abstract] [Full Text]
Golgher, D., Korangy, F., Gao, B., Gorski, K., Jaffee, E., Edidin, M., Pardoll, D. M., Elliott, T. (2001). An Immunodominant MHC Class II-Restricted Tumor Antigen Is Conformation Dependent and Binds to the Endoplasmic Reticulum Chaperone, Calreticulin. J. Immunol. 167: 147-155 [Abstract] [Full Text]
Beatty, G. L., Paterson, Y. (2001). IFN-{{gamma}}-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-{{gamma}}. J. Immunol. 166: 2276-2282 [Abstract] [Full Text]
Ohlen, C., Kalos, M., Hong, D. J., Shur, A. C., Greenberg, P. D. (2001). Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen. J. Immunol. 166: 2863-2870 [Abstract] [Full Text]
Fallarino, F., Grohmann, U., Bianchi, R., Vacca, C., Fioretti, M. C., Puccetti, P. (2000). Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo. J. Immunol. 165: 5495-5501 [Abstract] [Full Text]
Schultz, E. S., Lethé, B., Cambiaso, C. L., Van Snick, J., Chaux, P., Corthals, J., Heirman, C., Thielemans, K., Boon, T., van der Bruggen, P. (2000). A MAGE-A3 Peptide Presented by HLA-DP4 Is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes. Cancer Res. 60: 6272-6275 [Abstract] [Full Text]
Plautz, G. E., Mukai, S., Cohen, P. A., Shu, S. (2000). Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors. J. Immunol. 165: 3656-3662 [Abstract] [Full Text]
Wan, Y., Bramson, J., Pilon, A., Zhu, Q., Gauldie, J. (2000). Genetically Modified Dendritic Cells Prime Autoreactive T Cells through a Pathway Independent of CD40L and Interleukin 12: Implications for Cancer Vaccines. Cancer Res. 60: 3247-3253 [Abstract] [Full Text]
Schiavoni, G., Mattei, F., Di Pucchio, T., Santini, S. M., Bracci, L., Belardelli, F., Proietti, E. (2000). Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030 [Abstract] [Full Text]
Jager, E., Jager, D., Karbach, J., Chen, Y.-T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., Knuth, A. (2000). Identification of NY-ESO-1 Epitopes Presented by Human Histocompatibility Antigen (HLA)-DRB4*0101-0103 and Recognized by CD4+ T Lymphocytes of Patients with NY-ESO-1-expressing Melanoma. JEM 191: 625-630 [Abstract] [Full Text]
Surman, D. R., Dudley, M. E., Overwijk, W. W., Restifo, N. P. (2000). Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen. J. Immunol. 164: 562-565 [Abstract] [Full Text]
Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., Ohta, A. (1999). Distinct Role of Antigen-specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication In Vivo. JEM 190: 617-628 [Abstract] [Full Text]
Rodolfo, M., Zilocchi, C., Accornero, P., Cappetti, B., Arioli, I., Colombo, M. P. (1999). IL-4-Transduced Tumor Cell Vaccine Induces Immunoregulatory Type 2 CD8 T Lymphocytes That Cure Lung Metastases Upon Adoptive Transfer. J. Immunol. 163: 1923-1928 [Abstract] [Full Text]
Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D., Schreiber, H. (1999). CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96: 8633-8638 [Abstract] [Full Text]
Siegel, C. T., Schreiber, K., Meredith, S. C., Beck-Engeser, G. B., Lancki, D. W., Lazarski, C. A., Fu, Y.-X., Rowley, D. A., Schreiber, H. (1999). Enhanced Growth of Primary Tumors in Cancer-prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein. JEM 191: 1945-1956 [Abstract] [Full Text]
Valmori, D., Pittet, M. J., Rimoldi, D., Lienard, D., Dunbar, R., Cerundolo, V., Lejeune, F., Cerottini, J.-C., Romero, P. (1999). An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer. Cancer Res. 59: 2167-2173 [Abstract] [Full Text]
Toes, R. E.M., Ossendorp, F., Offringa, R., Melief, C. J.M. (1999). CD4 T Cells and Their Role in Antitumor Immune Responses. JEM 189: 753-756 [Full Text]
Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M.M., Boon, T., van der Bruggen, P. (1999). Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes. JEM 189: 767-778 [Abstract] [Full Text]
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H. (1998). The Central Role of CD4+ T Cells in the Antitumor Immune Response. JEM 188: 2357-2368 [Abstract] [Full Text]
Kagamu, H., Shu, S. (1998). Purification of L-Selectinlow Cells Promotes the Generation of Highly Potent CD4 Antitumor Effector T Lymphocytes. J. Immunol. 160: 3444-3452 [Abstract] [Full Text]
Schultz, K., Klarnet, J., Gieni, R., HayGlass, K., Greenberg, P. (1990). The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249: 921-923 [Abstract]